Welcure Drugs & Pharmaceuticals Ltd
₹ 10.7
-1.38%
22 May
- close price
About
Incorporated in 1992, Welcure Drugs And Pharmaceuticals Ltd used to manufacture pharmaceuticals products[1]
Key Points
- Market Cap ₹ 121 Cr.
- Current Price ₹ 10.7
- High / Low ₹ 15.8 / 4.30
- Stock P/E 64.2
- Book Value ₹ 9.05
- Dividend Yield 0.00 %
- ROCE -12.6 %
- ROE -11.9 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.18 times its book value
Cons
- Company has a low return on equity of -3.02% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Castings, Forgings & Fastners Industry: Castings & Forgings
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Upcoming result date: 29 May 2025
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.04 | 0.05 | 0.10 | 0.09 | 0.05 | 0.08 | 0.08 | 0.13 | 0.11 | 0.00 | 0.00 | 33.39 | |
| 0.04 | 0.05 | 0.04 | 0.06 | 0.06 | 0.07 | 0.08 | 0.09 | 0.07 | 0.09 | 0.14 | 0.23 | 31.03 | |
| Operating Profit | -0.01 | -0.01 | 0.01 | 0.04 | 0.03 | -0.02 | 0.00 | -0.01 | 0.06 | 0.02 | -0.14 | -0.23 | 2.36 |
| OPM % | -33.33% | -25.00% | 20.00% | 40.00% | 33.33% | -40.00% | 0.00% | -12.50% | 46.15% | 18.18% | 7.07% | ||
| 0.02 | 0.01 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.09 | 0.06 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.03 |
| Profit before tax | 0.01 | 0.00 | 0.01 | 0.09 | 0.03 | -0.02 | 0.00 | -0.01 | 0.06 | 0.02 | 0.10 | -0.18 | 2.39 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||
| 0.01 | 0.00 | 0.01 | 0.09 | 0.03 | -0.02 | 0.00 | -0.01 | 0.06 | 0.02 | 0.10 | -0.17 | 1.88 | |
| EPS in Rs | 0.01 | 0.00 | 0.01 | 0.07 | 0.02 | -0.01 | 0.00 | -0.01 | 0.04 | 0.01 | 0.07 | -0.13 | -0.07 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 18700% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 83% |
| 3 Years: | 23% |
| 1 Year: | 80% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -3% |
| Last Year: | -12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 12.12 | 13.44 | 13.44 | 112.44 |
| Reserves | -12.20 | -12.20 | -12.19 | -12.11 | -12.08 | -12.10 | -12.09 | -12.10 | -12.05 | -12.03 | -11.92 | -12.10 | -10.61 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.13 | 0.13 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 168.01 | |
| Total Liabilities | 0.05 | 0.05 | 0.06 | 0.01 | 0.04 | 0.02 | 0.03 | 0.02 | 0.07 | 0.09 | 1.53 | 1.37 | 269.84 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.02 | 0.03 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 |
| 0.05 | 0.05 | 0.06 | 0.01 | 0.04 | 0.02 | 0.03 | 0.02 | 0.07 | 0.09 | 1.30 | 1.35 | 269.81 | |
| Total Assets | 0.05 | 0.05 | 0.06 | 0.01 | 0.04 | 0.02 | 0.03 | 0.02 | 0.07 | 0.09 | 1.53 | 1.37 | 269.84 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.00 | 0.01 | -0.05 | 0.02 | -0.01 | 0.00 | -0.01 | 0.04 | 0.02 | 0.11 | -0.13 | |
| 0.02 | -0.02 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.17 | -0.02 | |
| Net Cash Flow | 0.03 | -0.02 | 0.01 | -0.02 | 0.02 | -0.01 | 0.00 | -0.01 | 0.04 | 0.02 | -0.06 | 0.02 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Working Capital Days | -1,581.67 | -1,186.25 | -876.00 | 36.50 | 81.11 | 73.00 | 45.62 | 0.00 | 0.00 | 0.00 | ||
| ROCE % | 120.00% | -66.67% | 0.00% | -40.00% | 133.33% | 25.00% | 9.94% | -12.59% |
Documents
Announcements
-
Board Meeting Intimation for For Consideration And Approval Of The Audited Financial Results
For The Quarter/Year Ended 31St March, 2025 Alongwith Statement Of Assets And Liabilities And Cash Flow
Statement For The Year Ended 31St March, 2025
2d - Board meeting on May 29 to approve FY25 audited financials and appoint secretarial auditor.
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 15 May
-
Announcement under Regulation 30 (LODR)-Change in Management
14 May - Appointment of Mr. Chintan Didawala as Managing Director from May 14, 2025, for five years.
-
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
14 May - Approved MOA alteration adding new business lines and increased authorised share capital to Rs.186 crore.
-
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Welcure Drugs & Pharmaceuticals Limited
14 May - Appointed new MD, expanded business objects, increased authorised capital to Rs.186 crore, shareholder approval pending.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Company manufactures and markets pharmaceuticals formulations in the form of tablets, capsules, dry syrups, antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarial, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilizers, sedatives and gastrointestinal.